Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in schizophrenia
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in…
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity candidates
Lucid Diligence Brief: Prolynx $70m Series A for long-acting obesity……
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B Professional…
Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer Ventures
Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer…
Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+ NSCLC
Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+…
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…
Lucid Diligence Brief: Avanzanite Bioscience €32m Series A
Lucid Diligence Brief: Avanzanite Bioscience €32m Series A Professional…
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing…
Lucid Diligence Brief: NEOK Bio $75M Series A
Lucid Diligence Brief: NEOK Bio $75M Series A Professional audiences only. Not…
Lucid Diligence Brief: Pelage Pharmaceuticals $120M Series B
Lucid Diligence Brief: Pelage Pharmaceuticals $120M Series B Professional…
Lucid Diligence Brief: Kardigan $254m Series B
Lucid Diligence Brief: Kardigan $254m Series B Professional audiences only. Not…
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040 Professional…